

Special Issue

Emerging Trends in Kidney Disease

Message from the Guest Editor

The field of nephrology is experiencing an unprecedented era of discovery and innovation, making it an incredibly exciting time for researchers and clinicians.

In the area of glomerular diseases and vasculitis, novel therapeutic agents are emerging that target specific molecular pathways, offering new hope for patients with previously refractory conditions.

In transplantation, the groundbreaking xenotransplantation trials mark significant progress in this field.

Pediatric nephrology is making significant strides, highlighting the importance of early intervention, in particular, pioneering treatments for severe congenital conditions that can improve survival rates.

These advancements underscore a vibrant period of innovation in nephrology. We invite you to contribute to this Special Issue of *Biomedicines*, sharing your research findings, clinical insights, and innovative approaches. Your contributions will help shape the future of kidney disease treatment and management, advancing scientific knowledge and significantly impacting patient care and outcomes.

Guest Editor

Dr. Andrea Angioi

Nephrology, Dialysis and Transplantation, ARNAS "Brotzu", Cagliari, Italy

Deadline for manuscript submissions

closed (30 June 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/206513

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).